Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

The goal of this clinical trial is to learn if Omega-3 fatty acids supplementation can enhance the efficacy of neoadjuvant immunotherapy in patients with locally advanced gastric and gastroesophageal junction adenocarcinoma. The main questions it aims to answer are: does Omega-3 supplementation improve the pathologic complete response (pCR) rate compared to standard neoadjuvant immunotherapy alone, and is there an increase in the major pathological response (MPR) rate with Omega-3 supplementation? Researchers will compare the group receiving Omega-3 supplementation with the control group receiving standard neoadjuvant immunotherapy to see if Omega-3 supplementation leads to better treatment outcomes. Participants will receive Omega-3 fatty acids supplements in conjunction with their prescribed neoadjuvant immunotherapy, undergo regular assessments of their pathologic response to treatment, and provide information on their nutritional status and quality of life throughout the study.

NCT Number	NCT07050524
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: First Affiliated Hospital of Suzhou Medical College, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Jiangning Hospital of Nanjing Medical University
Conditions	Gastric Cancer Stage III
Enrollment	80 participants
Start Date	2025-09-01
Primary Completion	2026-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-03